中国血液净化

中国血液净化 ›› 2017, Vol. 16 ›› Issue (08): 512-515.doi: 10.3969/j.issn.1671-4091.2017.08.003

• 专题与讲座 • 上一篇    下一篇

红细胞生成素抵抗及其介导纯红细胞再生障碍性贫血的诊治新进展

张舒1,董伟1,梁馨苓1   

  1. 1. 广东省人民医院肾内科， 广东省医学科学院
  • 收稿日期:2017-05-05 修回日期:2017-06-22 出版日期:2017-08-12 发布日期:2017-08-12
  • 通讯作者: 梁馨苓 xinlingliang_ggh@163.com E-mail:xinlingliang_ggh@163.com
  • 基金资助:

    国家临床重点专科建设项目国家自然科学基金（81570609）

Recent advances in the erythropoietin resistance and the pure red cell aplasia induced by anti-erythropoietin antibody

  • Received:2017-05-05 Revised:2017-06-22 Online:2017-08-12 Published:2017-08-12
  • Contact: Xin-Ling Liang E-mail:xinlingliang_ggh@163.com

PDF

676

摘要： 目前贫血仍是导致慢性肾脏病(chronic kidney disease,CKD)患者死亡的常见并发症之一，尽管红细胞生成素(erythropoietin,EPO)得到广泛应用并改善了CKD 患者的贫血，但仍有部分患者因存在EPO 抵抗而难以维持理想的血红蛋白水平，甚至极少数患者出现抗EPO 抗体介导的纯红细胞再生障碍性贫血(pure red cell aplasia, PRCA)。因EPO 抵抗及其介导的PRCA 发病机制及临床诊疗尚不十分明确，导致发病率有逐年增加趋势。本文就EPO抵抗及其介导的PRCA 近期研究进展进行介绍。

关键词: 红细胞生成素, 纯红细胞再生障碍性贫血, 慢性肾脏病

Abstract: Anemia is one of the common complications in chronic kidney disease (CKD) patients. Although erythropoietin- stimulating agents (ESAs) have been widely applied and are effective for anemia in CKD patents, it is impossible for some patients to maintain hemoglobin to the recommended level. Pure red cell aplasia (PRCA) induced by anti- erythropoietin antibody is present in a few cases. The pathogenesis of EPO resistance and anti-EPO antibody induced PRCA are unclear, and the prevalence of these abnormalities become increased. Here we discuss the recent advances in EPO resistance and anti-erythropoietin antibody induced PRCA.

Key words: erythropoietin, pure red cell aplasia, chronic kidney disease